Nature Reviews Drug Discovery 14, 591–592 (2015)
The description of the reanalysis of the EXPEDITION 1, 2 and EXT trials of solanezumab on p592 was inaccurate, and it is the last patient visit for the EXPEDITION 3 trial that is due in October 2016, not the final results. Changes have been made to correct these errors in the online version of the article.
Additional information
The online version of the original article can be found at 10.1038/nrd4709
Rights and permissions
About this article
Cite this article
Reardon, S. Erratum: Alzheimer antibody drugs show questionable potential. Nat Rev Drug Discov 14, 804 (2015). https://doi.org/10.1038/nrd4772
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4772
